Results 181 to 190 of about 73,124 (298)

Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis. [PDF]

Signal Transduct Target Ther
Fang XQ, Lim S, Lee YM, Lim CH, Kim HB, Joo JH, Han SW, Kim S, Kim JH, Na KJ, Park S, Kim YT, Park J, Park J, Lee JS, Shin EY, Kim EG, Shin HW, Lim JH.   +18 more
europepmc   +1 more source

Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT

American Journal of Hematology, Volume 101, Issue 8, Page 1790-1798, August 2026.
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack, Noah P. Splinter, Emily E. Mauch, Leben Tefera, Morayma Reyes Gil, Sakshi Jasra, Andrew Goodwin, Kristi J. Smock, Hadiyah Ahmad, Aneel Ashrani, Nathaniel L. Robinson, Ana I. Casanegra, Curtis G. Jones, Shannon M. Pechauer, Erin Yttre, Richard H. Aster, Mindy C. Kohlhagen, Rachel R. Leger, Gretchen Johns, David L. Murray, Lu Zhou, Demin Wang, Renren Wen, Dong Chen, Rajiv K. Pruthi, Anand Padmanabhan   +25 more
wiley   +1 more source

A Lung-Targeted Carrier of Carbon Monoxide for Idiopathic Pulmonary Fibrosis Therapy. [PDF]

ACS Nano
Guo W, Huang S, Zhang J, Zhang X, Yang J, Bao Y, Zhang J.   +6 more
europepmc   +1 more source

Lung Pericytes: Molecular Mechanisms, Signaling Pathways, and Roles in Pulmonary Diseases

Comprehensive Physiology, Volume 16, Issue 4, August 2026.
Central role of pericytes across major pulmonary diseases. Conceptual wheel diagram illustrating the central role of lung pericytes across diverse pulmonary disease states. A pericyte positioned at the center expresses canonical markers, including PDGFRβ, CD146, and NG2, and connects radially to five major disease contexts.
Stuti Agarwal, Anuradha Bankar, Vinicio A. de Jesus Perez   +2 more
wiley   +1 more source

Cellular Senescence in Idiopathic Pulmonary Fibrosis: Molecular Mechanisms, Pathogenic Networks, and Emerging Therapeutic Targets. [PDF]

Diseases
Baurzhan MB, Gulyayev AE, Absattarova KS, Kairgeldina SA, Abzaliyev K, Izbassarova A, Lepessova M, Absatarova K.   +7 more
europepmc   +1 more source

From scarring to healing: Emerging regenerative therapies for pulmonary fibrosis using MSCs and exosomes

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
MSCs exert anti‐inflammatory, anti‐fibrotic and regenerative effects in pulmonary fibrosis. MSC‐derived exosomes reproduce many therapeutic benefits of parental MSCs. Preconditioning and genetic modification improve MSC therapeutic performance. Current preclinical and clinical evidence supports the translational potential of MSC‐based therapies ...
Hajar Nasiri, Farbod Khosravi, Fatemeh Eskandari, Tahereh Manoochehrabadi, Ali Samadikuchaksaraei, Ehsan Lotfi, Jila Majidi, Fatemeh Rafati, Zeynab Ghorbani   +8 more
wiley   +1 more source

Towards causal validation and clinical translation of the PAK2-fibroblast axis in idiopathic pulmonary fibrosis. [PDF]

Eur Respir J
Sun M, Zang D, Chen J.
europepmc   +1 more source

Targeting fibrosis in the treatment of lower urinary tract dysfunction

The Journal of Pathology, Volume 269, Issue 4-5, Page 493-503, August 2026.
Abstract Benign prostatic hyperplasia (BPH) is a widely prevalent age‐associated disease that is the main contributor to lower urinary tract dysfunction (LUTD) in aging men. Although prostate fibrosis has been recognized as a contributor to BPH pathophysiology, there are not any clinically available therapeutics that target this aspect of disease ...
Ajinkya R Limkar, Sophia M Vrba, Emily A Ricke, Zsuzsanna Fabry, Matthew S Lee, Kevin T McVary, William A Ricke   +6 more
wiley   +1 more source

Advances in our understanding of distal progenitors in idiopathic pulmonary fibrosis: implications for novel therapeutics. [PDF]

Eur Respir J
Snoeck HW.
europepmc   +1 more source

A Proposed Clinical Diagnostic Framework for Short Telomere Syndrome

Clinical Genetics, Volume 110, Issue 2, Page 139-149, August 2026.
We propose a phenotype‐based diagnostic framework for short telomere syndrome that integrates age‐adjusted telomere length, phenotypic manifestations, and genetic findings, where available. The framework is intended to guide clinical evaluation, longitudinal surveillance, and individualized management while acknowledging limitations in current telomere
Andrew Courtwright, Richard A. King, Jennie Vagher, Cate T. Levy, Juan Gallegos F. Orozco, Luis FZ Batista, Afaf Osman, Srinivas Tantavahi, Mary Beth Scholand   +8 more
wiley   +1 more source